Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment Proceedings of a Workshop (2016) / Chapter Skim
Currently Skimming:
Appendix B: Workshop Agenda
Appendix B: Workshop Agenda
Pages 105-110
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 105... ...
Appendix B Workshop Agenda FEBRUARY 29, 2016 7:30 am Registration 8:00 am Welcome from the National Cancer Policy Forum Michael Caligiuri, The Ohio State University Comprehensive Cancer Center Chair, National Cancer Policy Forum Overview of the Workshop Samir N Khleif, Georgia Cancer Center at Augusta University Planning Committee Chair 8:15 am Session 1: Overview of the State of the Science and Unique Policy Challenges in Developing Immunotherapies for Cancer Deborah Schrag, Dana-Farber Cancer Institute Moderator: Personalized immunotherapy • Steven Rosenberg, National Cancer Institute 105
|
From page 106... ...
W Center for Drug Evaluation and Research Panel Discussion – Speakers Plus: Allen Wensky, FDA Center for Biologics Evaluation and Research 12:15 pm Lunch Break
|
From page 107... ...
APPENDIX B 107 1:00 pm Session 3: Challenges in Trial Design for Immunotherapies and Combinations Moderator: Michael Caligiuri, The Ohio State University Comprehensive Cancer Center Novel trial designs to assess early clinical efficacy of immunotherapies • National Cancer Institute R ich Simon, Biomarker integration in clinical trials for immunotherapies • Lisa Butterfield, University of Pittsburgh Strategies for personalized vaccines • Singh, Immatics Biotechnologies H arpreet Strategies for personalized cell therapy • avid Porter, University of Pennsylvania D FDA perspectives • ajeshwari Sridhara, FDA Center for Drug Evaluation R and Research • eter Bross, FDA Center for Biologics Evaluation and P Research Panel Discussion 3:10 pm Break 3:25 pm Session 4: Expanding Opportunities for Collaboration and Information Exchange Moderator: Amy Abernethy, Flatiron Health Trans-IT interoperability • rik Perakslis, Takeda Pharmaceuticals E Issues in data integration and sharing for novel therapies • ary Horowitz, Medical College of Wisconsin M
|
From page 108... ...
108 POLICY ISSUES FOR CANCER IMMUNOTHERAPY Infrastructure for clinical data exchange • my Abernethy, Flatiron Health A Bio/pharma collaboration in the precompetitive space • Averbuch, Bristol Myers-Squibb Steve Panel Discussion 5:25 pm Day 1 Wrap-Up MARCH 1, 2016 7:30 am Registration 8:00 am Session 5: Implementation in Clinical Practice Moderator: Malcolm Brenner, Baylor College of Medicine Scaling cellular therapies for clinical use • ark Dudley, Novartis M Technology assessment • ngela Thomas, UK National Health Service A Addressing adverse events in immunotherapy • amy Ibrahim, AstraZeneca R Clinical practice and physician training needs for immunotherapy • Wolchok, Memorial Sloan Kettering Cancer Center Jedd Patient and family education • ee Schwartzberg, Association of Community Cancer L Centers Panel Discussion 10:00 am Break
|
From page 109... ...
APPENDIX B 109 10:15 am Session 6: Value of Immunotherapy and Combination Therapies Moderator: Samir N Khleif, Georgia Cancer Center at Augusta University Industry perspectives • avid Kaufman, Merck D • ee Krug, Bristol Myers-Squibb L • reg Rossi, AstraZeneca G Centers for Medicare & Medicaid Services perspective • James Rollins, Office of Clinical Standards and Quality Private payer perspective • ee Newcomer, UnitedHealthcare L Health economist perspective • Ramsey, Fred Hutchinson Cancer Research Center Scott Patient advocacy perspective • wen Darien, Cancer Support Community G 11:30 am Workshop Wrap-Up 11:45 am Adjourn
|
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.